Pinilla Marta Suárez, Stoner Charlotte R, Knapp Martin, Nachev Parashkev, Rossor Martin
Clinical Neuroscience Laboratory, Center for Biomedical Technology, Universidad Politécnica de Madrid, Madrid, Spain.
UCL Queen Square Institute of Neurology, University College London, London, UK.
Brain Behav. 2025 Jan;15(1):e70200. doi: 10.1002/brb3.70200.
The cognitive side-effects of medication are common, but often overlooked in practice, and not routinely considered in interventional trials or post-market surveillance. The cognitive footprint of a medication seeks to quantify the impact of its cognitive effects based on magnitude, duration, and interaction with other factors, evaluated across the exposed population.
Bayesian multivariable regression analysis of retrospective population-based cross-sectional cohorts.
We replicate positive and negative cognitive effects of commonly used medications in UK Biobank, and extend observed associations to two additional cohorts, the EPIC Norfolk, and the Caerphilly Prospective Cohort. We quantify the resultant cumulative impact at the population level given known patterns of prescribing and compare it with exemplar common diseases.
The cognitive side-effects of commonly used drugs may have significant impact at the population level. Consideration should be given to a routine structured assessment of cognition in interventional trials and post-market surveillance.
药物的认知副作用很常见，但在实际中常常被忽视，在干预试验或上市后监测中也未被常规考虑。药物的认知足迹旨在根据在暴露人群中评估的严重程度、持续时间以及与其他因素的相互作用，对其认知效应的影响进行量化。
基于回顾性人群的横断面队列进行贝叶斯多变量回归分析。
我们在英国生物银行中重现了常用药物的正向和负向认知效应，并将观察到的关联扩展到另外两个队列，即诺福克欧洲癌症与营养前瞻性调查（EPIC Norfolk）和卡菲利前瞻性队列。我们根据已知的处方模式，在人群层面量化由此产生的累积影响，并将其与典型常见疾病进行比较。
常用药物的认知副作用可能在人群层面产生重大影响。在干预试验和上市后监测中，应考虑对认知进行常规结构化评估。
